Liquidia (LQDA) Capital Expenditures Growth (1y) (2021 - 2026)
Liquidia (LQDA) Capital Expenditures Growth (1y) (2021 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.01 Bn | 87.15 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.89 Bn | 32.15 Bn | 1.97 Bn | 32.28% |
| 3 | Zoetis | 32.48 Bn | 30.54 Bn | 1.62 Bn | -38.20% |
| 4 | Takeda Pharmaceutical | 27.52 Bn | 23.46 Bn | 4.39 Bn | -15.72% |
| 5 | United Therapeutics | 23.14 Bn | 20.99 Bn | 648.10 Mn | 32.98% |
| 6 | RedHill Biopharma | 21.76 Bn | 21.76 Bn | - | - |
| 7 | Viatris | 20.35 Bn | 18.55 Bn | 1.16 Bn | -6.34% |
| 8 | Neurocrine Biosciences | 17.73 Bn | 16.41 Bn | 800.70 Mn | -86.92% |
| 9 | Elanco Animal Health | 12.56 Bn | 12.14 Bn | 785.00 Mn | -21.54% |
| 10 | Liquidia | 7.62 Bn | 7.39 Bn | 121.79 Mn | 42.43% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 42.43% |
| Dec 31, 2025 | 98.70% |
| Sep 30, 2025 | -69.90% |
| Jun 30, 2025 | -2,029.61% |
| Mar 31, 2025 | 488.30% |
| Dec 31, 2024 | -1,775.24% |
| Sep 30, 2024 | 537.26% |
| Jun 30, 2024 | -162.55% |
| Mar 31, 2024 | 114.75% |
| Dec 31, 2023 | -58.04% |
| Sep 30, 2023 | 405.32% |
| Jun 30, 2023 | 2,109.09% |
| Mar 31, 2023 | 9,250.00% |
| Dec 31, 2022 | 2,355.00% |
| Jun 30, 2022 | -91.27% |
| Mar 31, 2022 | 89.74% |
| Dec 31, 2021 | 105.15% |
| Jun 30, 2021 | 4,300.00% |
| Mar 31, 2021 | -1,400.00% |